Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT03939533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03939533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2019
Completion date
January 3, 2022
Enrollment
64 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorder